Norovirus Treatment Market Report 2026

The norovirus treatment market size has grown rapidly in recent years. It will grow from $1.94 billion in 2025 to $2.15 billion in 2026 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to limited awareness of norovirus management, reliance on hospital-based treatments, insufficient homecare infrastructure, lack of standardized symptom management protocols, low adoption of probiotics and zinc supplementation.

The norovirus treatment market size is expected to see rapid growth in the next few years. It will grow to $3.22 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to growing demand for oral rehydration solutions, expansion of homecare services and telemedicine, increasing pediatric and elderly population focus, development of targeted supportive care therapies, rising healthcare expenditure and awareness campaigns. Major trends in the forecast period include increasing adoption of oral rehydration therapies, rising use of intravenous fluids in severe cases, growth in homecare and remote treatment options, expanded use of anti-diarrheal and symptom management drugs, focus on pediatric and geriatric norovirus care.

The rising prevalence of infectious diseases is anticipated to drive the growth of the norovirus treatment market in the coming years. Infectious diseases are conditions caused by bacteria, viruses, fungi, or parasites that spread among people and include illnesses such as influenza, tuberculosis, HIV/AIDS, malaria, and norovirus. The incidence of infectious diseases is increasing due to urban overcrowding, which enables more rapid transmission of pathogens within densely populated areas. Norovirus treatment helps mitigate the impact of infectious diseases by effectively managing symptoms and reducing transmission through appropriate hydration, hygiene, and isolation measures. For instance, in March 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, approximately 10.8 million people worldwide contracted tuberculosis in 2023, including 6 million men, 3.6 million women, and 1.3 million children. Therefore, the increasing prevalence of infectious diseases is fueling the growth of the norovirus treatment market.

Major companies operating in the norovirus treatment market are concentrating on the development of innovative approaches, such as advanced mRNA vaccines, to speed up targeted immunization, strengthen protection against severe infections, and lower the global burden of norovirus-related diseases. Advanced mRNA vaccines are next-generation immunization technologies that utilize engineered messenger RNA to direct cells to produce specific proteins, thereby triggering a targeted immune response with enhanced stability, effectiveness, and adaptability against a range of infectious diseases. For example, in October 2024, Moderna Inc., a US-based biotechnology company, partnered with the UK Health Security Agency (UKHSA), a UK-based government organization, to launch the world’s first Phase 3 clinical trial of an mRNA norovirus vaccine (mRNA-1403) in the UK. This trial introduces a vaccine designed to combat highly contagious norovirus by prompting the body to generate viral proteins that stimulate a robust immune response without the use of live virus. Key features of this initiative include the use of stabilized mRNA for improved durability, rapid development capabilities to address evolving strains, and the ability to induce both antibody and T-cell immune responses.

In March 2024, Kenvue Inc., a US-based consumer healthcare company, entered into a partnership with the Association of Physicians of India (API) to advance public health awareness and preventive care programs. Through this collaboration, Kenvue seeks to improve clinical guidance on hydration and energy management for hospitalized patients with non-diarrheal conditions by supporting evidence-based recommendations developed jointly with the Association of Physicians of India. The Association of Physicians of India (API) is an India-based professional organization representing physicians specializing in internal medicine.

Major companies operating in the norovirus treatment market are Abbott Laboratories, Reckitt Benckiser Group plc, Nestlé Health Science, Otsuka Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Lupin Limited, Mylan (Viatris Inc.), Perrigo Company plc, Haleon plc, Church & Dwight Co. Inc., GlaxoSmithKline Consumer Healthcare, Sanofi Consumer Healthcare, Pfizer Consumer Healthcare, Ferring Pharmaceuticals, Fresenius Kabi AG, Baxter International Inc., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Torrent Pharmaceuticals Ltd., Alkem Laboratories Ltd., Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Pfizer Healthcare India Pvt. Ltd., Mead Johnson Nutrition (Reckitt), Danone Nutricia, Amneal Pharmaceuticals Inc., Ajanta Pharma Ltd.

North America was the largest region in the norovirus treatment market in 2025. The regions covered in the norovirus treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the norovirus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the norovirus treatment market by increasing the cost of imported intravenous fluids, electrolytes, and pharmaceutical-grade antipyretics. Segments like crystalloids, lactated ringer’s solution, and pediatric electrolyte solutions are particularly impacted, with regions such as North America and Asia-Pacific facing supply chain disruptions. While tariffs raise treatment costs, they also encourage local manufacturing of supportive care products and development of cost-effective alternatives, strengthening domestic healthcare resilience.

The norovirus treatment market research report is one of a series of new reports that provides norovirus treatment market statistics, including norovirus treatment industry global market size, regional shares, competitors with a norovirus treatment market share, detailed norovirus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the norovirus treatment industry. This norovirus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Norovirus treatment focuses on supportive care to ease symptoms such as vomiting, diarrhea, and abdominal pain caused by the infection. It mainly includes maintaining proper hydration, ensuring adequate rest, and managing symptoms, as there is currently no specific antiviral therapy available for norovirus.

The primary treatment options for norovirus include electrolytes, intravenous fluids, antipyretics, analgesics, anti-diarrheal medications, and others. Electrolytes are essential minerals that carry an electric charge and support critical body functions such as nerve transmission, muscle activity, fluid balance, and pH regulation. Diagnostic approaches include stool testing, bacterial culture tests, and other methods. These treatments are administered through oral, intravenous, or subcutaneous routes and are used by end users such as hospitals, clinics, and homecare settings.

The norovirus treatment market includes revenues earned by entities by providing services such as symptom management, rehydration therapy, and stool tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The norovirus treatment market also includes sales of oral rehydration solutions (ORS), anti-nausea medications, thermometers, disinfectants, and cleaning products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.